Masahiro Takada, Michio Yoshimura, Takeshi Kotake, Kosuke Kawaguchi, Ryuji Uozumi, Masako Kataoka, Hironori Kato, Hiroshi Yoshibayashi, Hirofumi Suwa, Wakako Tsuji, et al. Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. Scientific Reports. 2022. 12. 1
Takamasa Mitsuyoshi, Yuka Ono, Ryo Ashida, Mikiko Yamashita, Hiroaki Tanabe, Sayaka Takebe, Mariko Tokiwa, Eiji Suzuki, Toshiyuki Imagumbai, Michio Yoshimura, et al. Multi-institutional phase II study of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for breast cancer in Japan: Kyoto Radiation Oncology Study Group (UPBEAT study). Japanese journal of clinical oncology. 2022. 53. 2. 174-178
Ayane Yamaguchi, Kosuke Kawaguchi, Hiroshi Ishiguro, Tatsuki R. Kataoka, Masae Torii, Chenfeng He, Nobuko Kawaguchi-Sakita, Masahiro Kawashima, Masahiro Takada, Eiji Suzuki, et al. The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research. JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
Noriko Senda, Nobuko Kawaguchi-Sakita, Masahiro Kawashima, Yukiko Inagaki-Kawata, Kenichi Yoshida, Tomomi Nishimura, Masahiro Takada, Eiji Suzuki, Yuki Kataoka, Fumiaki Sato, et al. Abstract P2-10-12: Relationship between predicted risks of carrying breast cancer susceptibility genes and the presence of germline variants in Japanese patients with primary breast cancer. Poster Session Abstracts. 2020
Soluble Type II Transforming Growth Factor-b Receptor Inhibits Tumorigenesis by Augmenting Host Antitumor Immunity
講演・口頭発表等 (14件)：
Exploration of metastatic brain tumor microenvironment specific molecular properties of immune cells and breast cancer cells
(2nd Annual Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier 2019)
Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer
(ESMO 2018)
Potential role of lipid metabolic network related to anti-tumor immune response in breast cancer microenvironment
(Cell Symposia 2018)
Gene expression profile of peripheral blood mononuclear cells in breast cancer patients may contribute to the identification and the immunological classification of breast cancer patients by blood test
(AACR 2017)
